TPD & Induced Proximity Summit Leaderboard
  • Monday, June 15, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 2

Author

Pharma Journalist 8869 posts 0 comments

EMA Begins Review of Bayer’s Stroke Drug Asundexian

Jun 10, 2026
Bayer has reached an important regulatory milestone for its investigational stroke prevention therapy as the European Medicines Agency (EMA) has validated and begun reviewing the…
Read More...

Beren Secures $300 Million for Rare Disease Expansion

Jun 10, 2026
Beren Therapeutics P.B.C. has raised $300 million in combined financing to support the development and potential commercialization of its investigational therapy adrabetadex, a…
Read More...

GSK to Acquire Nuvalent in $10.6 Billion Oncology Deal

Jun 10, 2026
GSK has agreed to acquire clinical-stage biotechnology company Nuvalent for approximately $10.6 billion, strengthening its oncology portfolio with a trio of targeted lung cancer…
Read More...

Aditxt Plans Public Spinout of Ignite Proteomics

Jun 10, 2026
Aditxt, Inc. has announced a definitive business combination agreement that will enable its wholly owned subsidiary, Ignite Proteomics, to become an independent publicly traded company…
Read More...

FDA Approves Extended Dosing Schedule for EBGLYSS

Jun 10, 2026
Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded dosing schedule of EBGLYSS® (lebrikizumab-lbkz), allowing eligible patients…
Read More...

FDA Expands HYMPAVZI Approval for More Hemophilia Patients

Jun 9, 2026
Pfizer has secured an expanded approval from the U.S. Food and Drug Administration (FDA) for HYMPAVZI® (marstacimab-hncq), broadening access to the once-weekly treatment for additional…
Read More...

Johnson & Johnson Buys Firefly Bio for $1 Billion

Jun 9, 2026
Johnson & Johnson has agreed to acquire biotechnology company Firefly Bio, Inc. in a deal valued at $1 billion in cash, strengthening its oncology pipeline with a novel platform…
Read More...

Incyte to Acquire Vega Therapeutics in $1.25 Billion Deal

Jun 9, 2026
Incyte has announced a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal valued at $1.25 billion upfront, with the potential…
Read More...

Owkin, Sanofi Expand AI Drug Development Partnership

Jun 8, 2026
Owkin and Sanofi have announced a new multi-year collaboration aimed at accelerating drug discovery and development through advanced artificial intelligence technologies. The agreement…
Read More...

Wegovy Pill Tops Three Million U.S. Prescriptions

Jun 7, 2026
Novo Nordisk has announced that its oral obesity treatment, Wegovy® (semaglutide) tablets 25 mg, has surpassed three million prescriptions in the United States within just over five…
Read More...
Prev Next
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
5th World ADC Summit South Korea
World TPD & Induced Proximity Summit South Korea
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
R&D Procurement & Sourcing in Pharma Summit
In Vivo Cell Engineering & Gene Editing Summit
PFS & Injectable Drug Delivery West Coast
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
World Bispecific & T-Cell Engager Summit South Korea
ALS Drug Development Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Chiesi Completes KalVista Acquisition, Expands Rare Disease Portfolio
  • IMAAVY Shows Strong Results in Rare Blood Disorder Trial
  • GSK’s Momelotinib Gains Orphan Status for VEXAS Syndrome
  • FDA Grants Priority Review for Tecentriq in Colon Cancer
  • China Approves Akeso’s Gumokimab for Plaque Psoriasis

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.